Merck to buy Hengrui Pharma's drug for up to $1.8B

Merck to buy Hengrui Pharma's drug for up to $1.8B

Merck & Co. Inc. said on Tuesday that it entered into an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for a cardiovascular disease drug HRS-5346, currently in a phase ...

Merck & Co. will pay up to $2 billion for the rights of the experimental drug for the heart of Jiangsu Hengrui Pharmaceuticals Co, the second recent incursion of the US pharmaceutical company into China for a novel drug. According to the agreement, Merck will pay $200 million in advance to develop and market the Hengrui Pharma pill, currently in the intermediate phase of human clinical trials, according to a statement issued on Tuesday. Merck ha…

MSD licenses Lp(a) heart drug from Hengrui in $2bn deal

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront

MSD enters agreement with Hengrui Pharma for Lp(a) inhibitor

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

Merck, Hengrui Launch Up-to-$2B+ Cardiometabolic Collaboration

Merck & Co. has agreed to license the oral small molecule Lipoprotein(a) [Lp(a)] inhibitor HRS-5346 from Jiangsu Hengrui Pharmaceuticals, through a licensing agreement that could generate up to $2 billion plus for the Chinese drug developer. Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, except in Greater China where Hengrui will retain rights. At China’s Peking University Third H…

Merck Makes Bold $2B Bet on Chinese Cardio Drug - USA Herald

Merck & Co. Inc. is making a high-stakes move in the cardiovascular drug market, announcing on Tuesday an exclusive licensing deal with Jiangsu Hengrui Pharmaceuticals Co. Ltd. The agreement, which sees Merck shelling out up to $2 billion, positions the company at the forefront of tackling a major global heart disease risk. Big Money, Big erck seals a $2B deal to acquire global rights to a Chinese cardio drug, HRS-5346, targeting Lp(a).